POLUS BioPharm Inc. (KOSE:A007630) agreed to acquire GTS Korea Co., Ltd. for KRW 3.6 billion on May 21, 2018. The deal value is payable in cash. For the year ending December 31, 2017, GTS Korea Co., Ltd. reported total assets of KRW 4.1 billion, total capital of KRW 1.7 billion, sales amount of KRW 21.7 billion and net profit of KRW 88.5 million. The Board of Directors of POLUS BioPharm Inc. passed a resolution on the deal on May 21, 2018.The scheduled acquisition date is May 29, 2018. POLUS BioPharm Inc. (KOSE:A007630) Cancelled the acquisition of GTS Korea Co., Ltd. on May 21, 2019.